Drug Trial Radar · NCT01474109
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Last checked: Nov 19, 2026Latest source record: Jan 6, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
289
Actual
Start
Dec 2011
Primary completion
Nov 2013
Study completion Nov 2013
Sponsor
- Lead sponsor
- ActelionJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Nov 18, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The DUAL-1 study is designed as a multicenter, double-blind two-period study with an initial fixed 16-week Period 1, followed by a Period 2 of variable duration. All patients completing Period 1 will continue on their original randomized treatment into Period 2, until the last randomized patient has completed Period 1. Patients will be randomized in a 1:1:1 ratio (macitentan 3mg: macitentan 10mg: placebo). The primary objective is to demonstrate the effect of macitentan on the reduction of the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcers. Other objectives include: * the evaluation of the efficacy of macitentan on hand functionality and DU burden at Week 16 in SSc patients with ongoing DU disease. * the evaluation of the safety and tolerability of macitentan in these patients. * the evaluation of the efficacy of macitentan on time to first DU complication during the entire treatment period.
Conditions
- Systemic Sclerosis
- Ulcers
Interventions
macitentan 3mgDrug
macitentan 3mg tablet once daily
macitentan 10mgDrug
macitentan 10mg tablet once daily
placeboDrug
matching placebo once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence Rate of New Digital Ulcers (DUs) up to Week 16Time frame: Baseline to week 16
Locations
77 sites in 18 countries. Site status is shown where the registry gives one.
University of Arizona Arthritis Center
Tucson, Arizona
UCLA Medical School - Rheumatology Division Rehabilitation Center
Los Angeles, California
Arthritis & Rheumatic Disease Specialties
Aventura, Florida
Sarasota Arthritis Research Center
Sarasota, Florida
Ochsner Medical Center
New Orleans, Louisiana
The Johns Hopkins University School of Medicine
Baltimore, Maryland
University of Michigan - Scleroderma Program
Ann Arbor, Michigan
Michigan State University
Grand Rapids, Michigan
University of Medicine & Dentistry of New Jersey, UMDNJ Scleroderma Program
New Brunswick, New Jersey
The Center for Rheumatology
Albany, New York
Shanahan Rheumatology and Immunotherapy, PLLC
Raleigh, North Carolina
The Cleveland Clinic Foundation
Cleveland, Ohio
Altoona Center for Clinical Research
Duncansville, Pennsylvania
University of Pittsburgh Department of Rheumatology
Pittsburgh, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Royal Adelaide Hospital
Adelaide, Australia
Wesley Hospital, Thoracic Department
Auchenflower, Australia
Royal Prince Alfred Hospital
Camperdown, Australia
St Vincent's Hospital
Fitzroy, Australia
Menzies Research Institute
Hobart, Australia
Gomel Regional Clinical Hospital
Homyel, Belarus
Healthcare Institution "Minsk City Hospital #1"
Minsk, Belarus
Healthcare Institution "Minsk Clinical Hospital #9"
Minsk, Belarus
Multiprofile Hospital for Active Treatment "Sveti Pantaleymon"
Pleven, Bulgaria
MHAT "Kaspela" EOOD Plovdiv - Rheumatology Ward
Plovdiv, Bulgaria
MHAT "Sv. Ivan Rilski" EAD Sofia - Clinic of Rheumatology
Sofia, Bulgaria
Rheumatology Research Associates
Edmonton, Alberta, Canada
St. Paul's Hospital
Vancouver, British Columbia, Canada
St. Joseph's Health Care
London, Ontario, Canada
Mount Sinai Hospital
Toronto, Ontario, Canada
CHUS Hopital Fleurimont
Sherbrooke, Quebec, Canada
Prosalud
Santiago, Chile
Private Office Marta Aliste
Santiago, Chile
Hospital San Juan de Dios
Santiago, Chile
Centro de Estudios Clinicos V
Viña del Mar, Chile
Medicity S.A.S.
Bucaramanga, Colombia
Servimed E.U.
Bucaramanga, Colombia
Klinicki Bolnicki Centar Osijek
Osijek, Croatia
University Hospital Centre Rijeka
Rijeka, Croatia
Klinički bolnički centar Split
Split, Croatia
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.